Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review

被引：0
|
作者：
Jalal Arabloo
Samad Azari
Hasan Abolghasem Gorji
Aziz Rezapour
Vahid Alipour
‬Seyed Jafar Ehsanzadeh
机构：
[1] Health Management Research Institute,Health Management and Economics Research Center
[2] Iran University of Medical Sciences,Hospital Management Research Center
[3] Health Management Research Institute,School of Health Management and Information Sciences
[4] Iran University of Medical Sciences,undefined
[5] Iran University of Medical Sciences,undefined
来源：
European Journal of Clinical Pharmacology | 2023年 / 79卷
关键词：
Brentuximab vedotin; Hodgkin lymphoma; Economic evaluation; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1443 / 1452
页数：9
相关论文
共 50 条
  • [1] Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review
    Arabloo, Jalal
    Azari, Samad
    Gorji, Hasan Abolghasem
    Rezapour, Aziz
    Alipour, Vahid
    Ehsanzadeh, Seyed Jafar
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (11) : 1443 - 1452
  • [2] Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
    A. J. N. Raymakers
    S. Costa
    D. Cameron
    D. A. Regier
    BMC Cancer, 20
  • [3] Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis
    Raymakers, A. J. N.
    Costa, S.
    Cameron, D.
    Regier, D. A.
    BMC CANCER, 2020, 20 (01)
  • [4] Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis
    Plattel, Wouter J.
    Bergamasco, Aurore
    Trinchese, Fabrizio
    Gavini, Francois
    Bent-Ennakhil, Nawal
    Zomas, Athanasios
    Castillon, Genaro
    Arredondo-Bisono, Teigna
    Cristarella, Tiffany
    Moride, Yola
    von Tresckow, Bastian
    LEUKEMIA & LYMPHOMA, 2021, 62 (14) : 3320 - 3332
  • [5] Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma
    Delea, Thomas E.
    Sharma, Arati
    Grossman, Aaron
    Eichten, Caitlin
    Fenton, Keenan
    Josephson, Neil
    Richhariya, Akshara
    Moskowitz, Alison J.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 117 - 130
  • [6] Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
    Xie, Shitong
    Sheng, Yanan
    Chuang, Ling-Hsiang
    Wu, Jing
    HEALTH ECONOMICS REVIEW, 2024, 14 (01):
  • [7] Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis
    Dada, Reyad
    Zekri, Jamal
    Al Saadi, Rawan
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (06) : 739 - 745
  • [8] Cost-Effectiveness Analysis of Consolidation With Brentuximab Vedotin for High-Risk Hodgkin Lymphoma After Autologous Stem Cell Transplantation
    Hui, Lucy
    von Keudell, Gottfried
    Wang, Rong
    Zeidan, Amer M.
    Gore, Steven D.
    Ma, Xiaomei
    Davidoff, Amy J.
    Huntington, Scott F.
    CANCER, 2017, 123 (19) : 3763 - 3771
  • [9] Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
    Macapagal, Sharina C.
    Lee, Hayoung
    Jabbar, Javaria Abdul
    Fjorden, Anna Caroline
    Joseph, Irene Tresa
    Kaur, Ramanpreet
    Mostafa, Jihan A.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
  • [10] Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective
    Large, Samuel
    Hettle, Robert
    Balakumaran, Arun
    Wu, Elise
    Borse, Rebekah H.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 16 - 25
12345